|
Study of the Safety and Efficacy of SU-011,248 in Adult Patients with Advanced Kidney Cancer Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Study of the Safety and Efficacy of SU-011,248 in Adult Patients with Advanced Kidney Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Study of the Safety and Efficacy of SU-011,248 in Adult Patients with Advanced Kidney Cancer Clinical research trials and Study of the Safety and Efficacy of SU-011,248 in Adult Patients with Advanced Kidney Cancer medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Study of the Safety and Efficacy of SU-011,248 in Adult Patients with Advanced Kidney Cancer. Study of the Safety and Efficacy of SU-011,248 in Adult Patients with Advanced Kidney Cancer Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Study of the Safety and Efficacy of SU-011,248 in Adult Patients with Advanced Kidney Cancer clinical trial. Subjects typically recieve the finest healthcare available for their Study of the Safety and Efficacy of SU-011,248 in Adult Patients with Advanced Kidney Cancer condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of the Safety and Efficacy of SU-011,248 in Adult Patients with Advanced Kidney Cancer  Study of the Safety and Efficacy of SU-011,248 in Adult Patients with Advanced Kidney Cancer
Study of the Safety and Efficacy of SU-011,248 in Adult Patients with Advanced Kidney Cancer
For Condition: Kidney Cancer
Status: No longer recruiting
Sponsor(s): Pfizer ,
Synopsis: The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion: Eligible patients must be at least 18 years of age with a diagnosis of metastatic kidney cancer. The patient's kidney cancer must have gotten worse during/after previous cytokine-based therapy was given. Any side effects from prior therapy must have subsided, and blood and urine tests must show adequate bone marrow, liver, and kidney function. Exclusion: Any of the following will exclude patients from study participation: prior treatment with any systemic therapy other than 1 prior cytokine-based treatment regimen; prior surgical resection of or irradiation to the only site of measurable disease; ongoing severe hematuria; other active second malignancy; cardiovascular diseases or conditions; known brain disease; known HIV-positive or AIDS-related illness; pregnant or breast-feeding women; current participation in other clinical trials; other severe acute or chronic medical conditions. Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.
Total Enrollment:
Location and Contact Information:
Research Center
Ann Arbor, Michigan, 48109
United States
Research Center
Chicago, Illinois, 60637
United States
Research Center
San Francisco, California, 94121
United States
Research Center
Los Angeles, California, 90095
United States
Research Center
San Francisco, California, 94115
United States
Research Center
Boston, Massachusetts, 02115
United States
Research Center
Las Vegas, Nevada, 89109
United States
Research Center
Monterey, California, 91754
United States
Research Center
Philadelphia, Pennsylvania, 19111
United States
Research Center
Mission Hills, California, 91345
United States
Research Center
Boston, Massachusetts, 02114
United States
Research Center
Madison, Wisconsin, 53792
United States
Research Center
Las Vegas, Nevada, 89128
United States
Research Center
Northridge, California, 91328
United States
Research Center
Henderson, Nevada, 89052
United States
Research Center
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: RTKC-0511-014;
Study Start Date: January 2003
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00054886
Other Kidney Cancer Studies:
1. High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
2. Fludarabine, Total-body Irradiation, Donor Peripheral Stem Cell Transplantation, and Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
3. Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
4. Chemotherapy in Treating Patients With Solid Tumors
5. Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract
Related Studies:
Other Kidney Cancer Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
Study of the Safety and Efficacy of SU-011,248 in Adult Patients with Advanced Kidney Cancer
|
|
|
|
|
|
|
|
